Leader
Gene therapy in autoimmune diseases
| The first 150 words of the full text of this article appear below. |
| |
Introduction |
|---|
Collectively, autoimmune diseases constitute a major, unmet, clinical challenge. Although no single autoimmune disorder is highly prevalent, there are over 80 of them, and 20% of the population is affected; approximately 75% of patients are women. Because these diseases are generally incurable and difficult to manage, there is a pressing need for novel approaches to their treatment. For reasons detailed below, we have proposed that gene therapy merits investigation in this regard.1
| |
Why genes? |
|---|
Traditional pharmacological approaches to treatment entail the
synthesis of small, diffusable compounds given orally or by injection.
These approaches have yet to provide ideal agents for use in autoimmune
diseases. Recent research, however, has identified a number of proteins
with the potential to improve treatment, but these are difficult to
administer long term. Gene transfer provides the opportunity to deliver
protein products, as well as therapeutic species of nucleic acids, such
as antisense RNA, much more efficiently than traditional
This article has been cited by other articles:
-
Vasoo, S, Hughes, G R.
(2005). Theory, targets and therapy in systemic lupus erythematosus. Lupus
14: 181-188
[Abstract]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
